Site-specific glycoengineering of targeting moieties
AssigneeGenzyme Corporation
InventorsLuis Avila, Clark Pan, Huawei Qiu, Qun Zhou
Life of this patent
Estimating the term…
Abstract
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
Claims20
A method of making an antibody, or antigen-binding fragment thereof, comprising at least one modified glycan, wherein the glycan comprises at least one moiety of Formula (IV):
- the method comprising reacting an effector moiety of Formula (I):
- NH2-Q-CON—X Formula (I),
- with a precursor antibody, or antigen-binding fragment thereof, comprising an oxidized glycan
- wherein:
- A) Q is NH or O;
- B) CON is a connector moiety;
- C) X is a targeting moiety that binds to a receptor on a cell, such that the antibody, or antigen-binding fragment thereof, is internalized by the cell;
- D) Gal is a galactose moiety;
- and
- E) Sia is a sialic acid moiety.
Dependencies are inferred from the claim text.